Liminatus Pharma (LIMN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$1.4M

Net income growth (year over year)

−1342.21%

Net margin

—

Return on equity

—

EPS (trailing twelve months)

−$3.42

Book value per share

$0.27

P/E (trailing twelve months)

—

Price to book

14.34

Debt to assets

91.17%

Payout ratio

—

Dividend yield

—

Company profile

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.

• How do I buy stock in Liminatus Pharma (LIMN)?

  LIMN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.